Palandri, Francesca http://orcid.org/0000-0001-8367-5668
Elli, Elena M.
Auteri, Giuseppe
Bonifacio, Massimiliano http://orcid.org/0000-0003-0716-1686
Benevolo, Giulia
Heidel, Florian H.
Paglia, Simona http://orcid.org/0000-0002-5016-7840
Trawinska, Malgorzata M.
Bosi, Costanza
Rossi, Elena
Tiribelli, Mario http://orcid.org/0000-0001-9449-2621
Tieghi, Alessia http://orcid.org/0000-0002-6911-4095
Iurlo, Alessandra http://orcid.org/0000-0002-4401-0812
Polverelli, Nicola http://orcid.org/0000-0001-6297-9697
Caocci, Giovanni http://orcid.org/0000-0002-6585-5187
Binotto, Gianni
Cavazzini, Francesco
Beggiato, Eloise
Cilloni, Daniela
Tatarelli, Caterina
Mendicino, Francesco
Miglino, Maurizio
Bocchia, Monica
Crugnola, Monica
Mazzoni, Camilla
Romagnoli, Andrea D.
Rindone, Giovanni
Ceglie, Sara
D’Addio, Alessandra
Santoni, Eleonora
Cattaneo, Daniele
Bartoletti, Daniela
Lemoli, Roberto M.
Krampera, Mauro http://orcid.org/0000-0002-7280-2040
Cuneo, Antonio
Semenzato, Gianpietro C. http://orcid.org/0000-0002-6061-4595
Latagliata, Roberto
Abruzzese, Elisabetta http://orcid.org/0000-0001-5228-6491
Vianelli, Nicola
Cavo, Michele http://orcid.org/0000-0003-4514-3227
Andriani, Alessandro
De Stefano, Valerio http://orcid.org/0000-0002-5178-5827
Palumbo, Giuseppe A. http://orcid.org/0000-0003-1859-6319
Breccia, Massimo http://orcid.org/0000-0003-1163-6162
Funding for this research was provided by:
Ministero della Salute (RC-2022-2773427, RC-2022-2773402)
Article History
Received: 11 January 2023
Revised: 28 March 2023
Accepted: 11 April 2023
First Online: 3 May 2023
Competing interests
: F.P. consultancy and honoraria from Novartis, Celgene, AOP, Sierra Oncology and CTI; G.Be. honoraria from Novartis, Janssen, Amgen, Takeda, BMS; A.Iu., M.Br. and M.Bo. honoraria from Novartis, BMS, Pfizer, Incyte; M.Cr honoraria from Novartis, Amgen; G.S. honoraria from Abbvie, Roche, Takeda; G.Bi. honoraria from Novartis, Incyte, BMS-Celgene, Pfizer; R.M.L. honoraria from Jazz, Pfizer, AbbVie, BMS, Sanofi, StemLine. F.H.H. consultancy for Novartis, CTI and Celgene and research funding from Novartis; M. Ca acted as consultant and received honoraria from Jannsen, BMS Celgene, SanoFI, GlaxoSmithKline, Takeda, Amgen, Oncopeptides, AbbVie, Karyopharm, and Adaptive. E. A. honoraria from Novartis, BMS, Pfizer, and Incyte. N.V. consultancy and honoraria from Novartis, Amgen, Sobi, Grifols e Sanofi. V.D.S. consultant honoraria and speaker fees from AbbVie, Alexion, Amgen, AOP Health, Argenx, Bristol Myers Squibb, Grifols, GlaxoSmithKline, Leo Pharma, Novartis, Novo Nordisk, Sanofi, SOBI, Takeda. D. C. honoraria from Novartis, BMS, Incyte and Pfizer. M.B. honoraria from Novartis, Incyte, Astrazeneca, Jannsen. G.A.P. honoraria from Abbvie, AOP, AstraZeneca, BMS Celgene, Novartis, Incyte, Jannsen, Takeda; M. T. consultancy and honoraria from Novartis. M. M. T. consultancy and honoraria from Novartis. F.C. honoraria from Novartis, Incyte, and Pfizer, R.L. honoraria from Novartis, Celgene, BMS, Janssen; E.R., A.D., E.S., A.A, S.C., M.K, N.P., G.A., S.P., D.B., A.D.R., C.M., G.C, G.R., E.M.E., M.F., A.C., E.B., C.T, C.B., D.C., M.M., A.T. have no conflict of interest to disclose.